Mr. Soriot isn’t expected to leave immediately, but the company reportedly hired headhunters to draw up a list of potential internal candidates. The Times reports that potential candidates could include AstraZeneca’s senior executives Mene Pangalos and Ruud Dobber.
The news comes after the drugmaker suffered a setback with the failure of a big lung cancer trial in November.
Mr. Soriot had promised to achieve at least $40 billion in sales by 2023, and the cancer drug setback pushes that goal further out of reach.
More articles on pharmacy:
Florida adds CVS, Walgreens to opioid lawsuit
Pfizer to hike price of 41 drugs in January
Bristol-Myers Squibb to lay off 69 employees in Florida
